{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:21:34Z","timestamp":1783635694358,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":107,"publisher":"Springer US","isbn-type":[{"value":"9781071650493","type":"print"},{"value":"9781071650509","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5050-9_27","type":"book-chapter","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:06:26Z","timestamp":1783634786000},"page":"425-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Strategies to Uncover Genes Involved in the Development of Prostate Cancer in Families with Multiple Cases"],"prefix":"10.1007","author":[{"given":"Luc\u00eda","family":"Chica-Redecillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cuenca-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Alvarez-Cubero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"27_CR1","doi-asserted-by":"crossref","unstructured":"Zhang W, Cao G, Wu F et al (2023) Global burden of prostate cancer and association with socioeconomic status, 1990\u20132019: a systematic analysisfrom the Global Burden of Disease Study. J Epidemiol Glob Health 13","DOI":"10.2139\/ssrn.4161709"},{"key":"27_CR2","doi-asserted-by":"crossref","unstructured":"Wang L, Lu B, He M et al (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 10","DOI":"10.3389\/fpubh.2022.811044"},{"key":"27_CR3","doi-asserted-by":"crossref","unstructured":"Shore ND, Morgans AK, El-Haddad G et al (2022) Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams. Target Oncol","DOI":"10.1007\/s11523-022-00925-7"},{"key":"27_CR4","doi-asserted-by":"crossref","unstructured":"Kici\u0144ski M, Vangronsveld J, Nawrot TS (2011) An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One 6","DOI":"10.1371\/journal.pone.0027130"},{"key":"27_CR5","unstructured":"International Agency for Research on Cancer Global Cancer Observatory: Cancer Today. https:\/\/gco.iarc.fr\/today\/en"},{"key":"27_CR6","unstructured":"American Cancer Society Key Statistics for Prostate Cancer. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html#:~:Text=Prostate%20cancer%20is%20the%20most,diagnosed%20cancer%20in%20the%20world"},{"key":"27_CR7","doi-asserted-by":"crossref","unstructured":"Howard N, Clementino M, Kim D et al (2019) New developments in mechanisms of prostate cancer progression. Semin Cancer Biol 57:111\u2013116","DOI":"10.1016\/j.semcancer.2018.09.003"},{"key":"27_CR8","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K et al (2023) 2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol 84(2):191\u2013206","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"27_CR9","doi-asserted-by":"crossref","unstructured":"Rafikova G, Gilyazova I, Enikeeva K et al (2023) Prostate cancer: genetics, epigenetics and the need for immunological biomarkers. Int J Mol Sci 24(16):12797","DOI":"10.3390\/ijms241612797"},{"key":"27_CR10","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72","DOI":"10.3322\/caac.21708"},{"key":"27_CR11","doi-asserted-by":"crossref","unstructured":"Zlotta AR, Egawa S, Pushkar D et al (2013) Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105(14):1050\u20131058","DOI":"10.1093\/jnci\/djt151"},{"key":"27_CR12","doi-asserted-by":"crossref","unstructured":"Raghallaigh HN, Bott SR (2022) The role of family history and germline genetics in prostate cancer disease profile and screening. In: Urologic Cancers. Exon Publications, Brisbane (AU)","DOI":"10.36255\/exon-publications-urologic-cancers-prostate-cancer-family-history-genetics"},{"key":"27_CR13","doi-asserted-by":"crossref","unstructured":"Mucci LA, Hjelmborg JB, Harris JR et al (2016) Familial risk and heritability of cancer among twins in Nordic countries. JAMA 315(1):68\u201376","DOI":"10.1001\/jama.2015.17703"},{"key":"27_CR14","doi-asserted-by":"crossref","unstructured":"Wu X, Gu J (2016) Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms. Ann Transl Med 4(10):206","DOI":"10.21037\/atm.2016.05.31"},{"key":"27_CR15","doi-asserted-by":"crossref","unstructured":"Lichtenstein P, Holm N V, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer\u2014analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78\u201385","DOI":"10.1056\/NEJM200007133430201"},{"key":"27_CR16","doi-asserted-by":"crossref","unstructured":"Nicolosi P, Ledet E, Yang S et al (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 5(4):523\u2013528","DOI":"10.1001\/jamaoncol.2018.6760"},{"key":"27_CR17","doi-asserted-by":"crossref","unstructured":"Bancroft EK, Page EC, Brook MN et al (2021) A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 22(11):1618\u20131631","DOI":"10.1016\/S1470-2045(21)00522-2"},{"key":"27_CR18","doi-asserted-by":"crossref","unstructured":"Xu J, Resurreccion WK, Shi Z et al (2022) Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis 25(3):422\u2013430","DOI":"10.1038\/s41391-021-00458-6"},{"key":"27_CR19","doi-asserted-by":"crossref","unstructured":"Parra-Soto S, Ahumada D, Petermann-Rocha F et al (2022) Association of meat, vegetarian, pescatarian and fish-poultry diets with risk of 19 cancer sites and all cancer: findings from the UK Biobank prospective cohort study and meta-analysis. BMC Med 20(1):79","DOI":"10.1186\/s12916-022-02257-9"},{"key":"27_CR20","doi-asserted-by":"crossref","unstructured":"Hardt L, Mahamat-Saleh Y, Aune D et al (2022) Plant-based diets and cancer prognosis: a review of recent research. Curr Nutr Rep 11(4):695\u2013716","DOI":"10.1007\/s13668-022-00440-1"},{"key":"27_CR21","doi-asserted-by":"crossref","unstructured":"Molina-Montes E, Salamanca-Fern\u00e1ndez E, Garcia-Villanova B et al (2020) The impact of plant-based dietary patterns on cancer-related outcomes: a rapid review and meta-analysis. Nutrients 12(7):2010","DOI":"10.3390\/nu12072010"},{"key":"27_CR22","doi-asserted-by":"crossref","unstructured":"Zhu Y, Li Q, Xu X (2020) Dietary inflammatory index and the risk of prostate cancer: a dose-response meta-analysis. Eur J Clin Nutr 74(7):1001\u20131008","DOI":"10.1038\/s41430-019-0500-3"},{"key":"27_CR23","doi-asserted-by":"crossref","unstructured":"Fu BC, Tabung FK, Pernar CH et al (2021) Insulinemic and inflammatory dietary patterns and risk of prostate cancer. Eur Urol 79(3):405\u2013412","DOI":"10.1016\/j.eururo.2020.12.030"},{"key":"27_CR24","doi-asserted-by":"crossref","unstructured":"Trudeau K, Rousseau MC, Parent M\u00c9 (2020) Extent of food processing and risk of prostate cancer: the Proteus study in Montreal, Canada. Nutrients 12(3):637","DOI":"10.3390\/nu12030637"},{"key":"27_CR25","unstructured":"Morris BJ, Matthews JG, Pabalan N et al (2021) Male circumcision and prostate cancer: a meta-analysis revisited. Can J Urol 28(4):10768\u201310776"},{"key":"27_CR26","doi-asserted-by":"crossref","unstructured":"Del Giudice F, Kasman AM, De Berardinis E et al (2020) Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. Fertil Steril 114(5):984\u2013996","DOI":"10.1016\/j.fertnstert.2020.04.042"},{"key":"27_CR27","doi-asserted-by":"crossref","unstructured":"Behboudi-Gandevani S, Bidhendi-Yarandi R, Panahi MH et al (2021) A systematic review and meta-analysis of male infertility and the subsequent risk of cancer. Front Oncol 11:696702","DOI":"10.3389\/fonc.2021.696702"},{"key":"27_CR28","doi-asserted-by":"crossref","unstructured":"Zhong H, Liu S, Wang Y et al (2022) Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 21(5):103084","DOI":"10.1016\/j.autrev.2022.103084"},{"key":"27_CR29","doi-asserted-by":"crossref","unstructured":"Ge Y, Shi Q, Yao W et al (2020) The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 23(1):53\u201358","DOI":"10.1038\/s41391-019-0177-7"},{"key":"27_CR30","doi-asserted-by":"crossref","unstructured":"Fang X, Wei J, He X et al (2018) Quantitative association between body mass index and the risk of cancer: a global meta-analysis of prospective cohort studies. Int J Cancer 143(7):1595\u20131603","DOI":"10.1002\/ijc.31553"},{"key":"27_CR31","doi-asserted-by":"crossref","unstructured":"Russo GI, Calogero AE, Condorelli RA et al (2020) Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male 23(2):132\u2013138","DOI":"10.1080\/13685538.2018.1455178"},{"key":"27_CR32","doi-asserted-by":"crossref","unstructured":"Moghoofei M, Keshavarz M, Ghorbani S et al (2019) Association between human papillomavirus infection and prostate cancer: a global systematic review and meta-analysis. Asia Pac J Clin Oncol 15(5):e59\u2013e67","DOI":"10.1111\/ajco.13124"},{"key":"27_CR33","doi-asserted-by":"crossref","unstructured":"Onyije FM, Hosseini B, Togawa K et al (2021) Cancer incidence and mortality among petroleum industry workers and residents living in oil producing communities: a systematic review and meta-analysis. Int J Environ Res Public Health 18(8):4343","DOI":"10.3390\/ijerph18084343"},{"key":"27_CR34","doi-asserted-by":"crossref","unstructured":"Togawa K, Leon ME, Lebailly P et al (2021) Cancer incidence in agricultural workers: findings from an international consortium of agricultural cohort studies (AGRICOH). Environ Int 157:106825","DOI":"10.1016\/j.envint.2021.106825"},{"key":"27_CR35","doi-asserted-by":"crossref","unstructured":"Krstev S, Knutsson A (2019) Occupationalrisk factors for prostate cancer: a meta-analysis. J Cancer Prev 24(2):91\u2013111","DOI":"10.15430\/JCP.2019.24.2.91"},{"key":"27_CR36","doi-asserted-by":"crossref","unstructured":"Berge LAM, Liu FC, Grimsrud TK et al (2023) Night shift work and risk of aggressive prostate cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort. Int J Epidemiol 52(4):1003\u20131014","DOI":"10.1093\/ije\/dyac235"},{"key":"27_CR37","doi-asserted-by":"crossref","unstructured":"Alif SM, Sim MR, Ho C et al (2022) Cancer and mortality in coal mine workers: a systematic review and meta-analysis. OEM 79(5):347\u2013357","DOI":"10.1136\/oemed-2021-107498"},{"key":"27_CR38","doi-asserted-by":"crossref","unstructured":"Rivera-izquierdo M, Mart\u00ednez-ruiz V, Castillo-ruiz EM et al (2020) Shift work and prostate cancer: an updated systematic review and meta-analysis. Int J Environ Res Public Health 17(4):1345","DOI":"10.3390\/ijerph17041345"},{"key":"27_CR39","doi-asserted-by":"crossref","unstructured":"Wendeu-Foyet MG, Bayon V, C\u00e9n\u00e9e S et al (2018) Night work and prostate cancer risk: results from the EPICAP Study. OEM 75(8):573\u2013581","DOI":"10.1136\/oemed-2018-105009"},{"key":"27_CR40","doi-asserted-by":"crossref","unstructured":"Jian Z, Ye D, Chen Y et al (2018) Sexual activity and risk of prostate cancer: a dose\u2013response meta-analysis. J Sex Med 15(9):1300\u20131309","DOI":"10.1016\/j.jsxm.2018.07.004"},{"key":"27_CR41","doi-asserted-by":"crossref","unstructured":"Crocetto F, Arcaniolo D, Napolitano L et al (2021) Impact of sexual activity on the risk of male genital tumors: a systematic review of the literature. Int J Environ Res Public Health, 18(16), 8500","DOI":"10.3390\/ijerph18168500"},{"key":"27_CR42","doi-asserted-by":"crossref","unstructured":"Rider JR, Wilson KM, Sinnott JA et al (2016) Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up. Eur Urol 70(6):974\u2013982","DOI":"10.1016\/j.eururo.2016.03.027"},{"key":"27_CR43","doi-asserted-by":"crossref","unstructured":"Beckmann KR, O\u2019Callaghan ME, Ruseckaite R et al (2017) Prostate cancer outcomes for men who present with symptoms at diagnosis. BJU Int 119(6):862\u2013871","DOI":"10.1111\/bju.13622"},{"issue":"2","key":"27_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389","journal-title":"World journal of oncology"},{"key":"27_CR45","unstructured":"NICE Prostate cancer: diagnosis and management | Guidance and guidelines | NICE"},{"key":"27_CR46","doi-asserted-by":"crossref","unstructured":"Sekhoacha M, Riet K, Motloung P et al (2022) Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules (Basel, Switzerland) 27(17):5730","DOI":"10.3390\/molecules27175730"},{"key":"27_CR47","unstructured":"Roberts MJ, Teloken P, Chambers SK et al (2000) Prostate Cancer Detection. In K. R. Feingold (Eds.) et al., Endotext. MDText.com, Inc."},{"key":"27_CR48","unstructured":"American Cancer Society Tests to Diagnose and Stage Prostate Cancer. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/detection-diagnosis-staging\/how-diagnosed.html"},{"key":"27_CR49","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244\u2013252","DOI":"10.1097\/PAS.0000000000000530"},{"key":"27_CR50","doi-asserted-by":"crossref","unstructured":"Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403\u2013417","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"27_CR51","unstructured":"National Cancer Institute (NIH) Prostate  Cancer \u00a0reatment (PDQ\u00ae)\u2013Health Professional Version"},{"key":"27_CR52","doi-asserted-by":"crossref","unstructured":"Sartor O, Coleman R, Nilsson S et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15(7):738\u2013746","DOI":"10.1016\/S1470-2045(14)70183-4"},{"key":"27_CR53","unstructured":"National Cancer Institute Hormone Therapy for Prostate Cancer"},{"key":"27_CR54","doi-asserted-by":"crossref","unstructured":"Cozar JM, Robles-Fernandez I, Martinez-Gonzalez LJ et al (2018) Genetic markers a landscape in prostate cancer. Mutat Res Rev Mutat Res 775:1\u201310","DOI":"10.1016\/j.mrrev.2017.11.004"},{"key":"27_CR55","doi-asserted-by":"crossref","unstructured":"Schaeffer EM, Srinivas S, Adra N et al (2023) Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. JNCCN 21(10):1067\u20131096","DOI":"10.6004\/jnccn.2023.0050"},{"key":"27_CR56","doi-asserted-by":"crossref","unstructured":"Cimadamore A, Rescigno P, Conteduca V et al (2023) SIUrO best practice recommendations to optimize BRCA 1\/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP). Virchows Archiv 483(5):579\u2013589","DOI":"10.1007\/s00428-023-03660-0"},{"key":"27_CR57","doi-asserted-by":"crossref","unstructured":"Taylor AK, Kosoff D, Emamekhoo H et al (2023) PARP inhibitors in metastatic prostate cancer. Front Oncol 13:1159557","DOI":"10.3389\/fonc.2023.1159557"},{"key":"27_CR58","doi-asserted-by":"crossref","unstructured":"Kensler KH, Baichoo S, Pathania S et al (2022) The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer. NPJ Precis Oncol 6(1):39","DOI":"10.1038\/s41698-022-00284-6"},{"key":"27_CR59","doi-asserted-by":"crossref","unstructured":"Vietri MT, D\u2019elia G, Caliendo G et al (2021) Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci 22(7):3753","DOI":"10.3390\/ijms22073753"},{"key":"27_CR60","unstructured":"Potter SR, Partin AW (2000) Hereditary and familial prostate cancer: biologic aggressiveness and recurrence. Rev Urol 2(1):35\u201336"},{"key":"27_CR61","doi-asserted-by":"crossref","unstructured":"Beebe-Dimmer JL, Kapron AL, Fraser AM et al (2020) Risk of prostate cancer associated with familial and hereditary cancer syndromes. J Clin Oncol 38(16):1807\u20131813","DOI":"10.1200\/JCO.19.02808"},{"key":"27_CR62","doi-asserted-by":"crossref","unstructured":"Brand\u00e3o A, Paulo P, Teixeira MR (2020) Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci 21(14):5036","DOI":"10.3390\/ijms21145036"},{"key":"27_CR63","unstructured":"National Cancer Institute Hereditary breast and ovarian cancer syndrome. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/hereditary-breast-and-ovarian-cancer-syndrome"},{"key":"27_CR64","doi-asserted-by":"crossref","unstructured":"Barber L, Gerke T, Markt SC et al (2018) Family history of breast or prostate cancer and prostate cancer risk. Clin Cancer Res 24(23):5910\u20135917","DOI":"10.1158\/1078-0432.CCR-18-0370"},{"key":"27_CR65","unstructured":"National Library of Medicine Lynch syndrome. https:\/\/medlineplus.gov\/genetics\/condition\/lynch-syndrome\/#inheritance"},{"key":"27_CR66","doi-asserted-by":"crossref","unstructured":"Haraldsdottir S, Hampel H, Wei L et al (2014) Prostate cancer incidence in males with Lynch syndrome. Genet Med 16(7):553\u2013557","DOI":"10.1038\/gim.2013.193"},{"key":"27_CR67","doi-asserted-by":"crossref","unstructured":"Ryan S, Jenkins MA, Win AK (2014) Risk of prostate cancer in lynch syndrome: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Soc Prev Oncol 23(3):437\u2013449","DOI":"10.1158\/1055-9965.EPI-13-1165"},{"key":"27_CR68","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) (2024) Prostate Cancer Early Detection"},{"key":"27_CR69","unstructured":"EAU Guidelines Edn. Presented at the EAU Annual Congress Paris April 2024."},{"key":"27_CR70","doi-asserted-by":"crossref","unstructured":"Parker C, Castro E, Fizazi K et al (2020) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119\u20131134","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"27_CR71","doi-asserted-by":"crossref","unstructured":"Tuffaha H, Edmunds K, Fairbairn D et al (2023) Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis 27(4):594\u2013603","DOI":"10.1038\/s41391-023-00676-0"},{"key":"27_CR72","doi-asserted-by":"crossref","unstructured":"Vysotskaia V, Kaseniit KE, Bucheit L et al (2020) Clinical utility of hereditary cancer panel testing: impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer 126(3):549\u2013558","DOI":"10.1002\/cncr.32572"},{"key":"27_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10689-024-00377-0","volume":"23","author":"M Vlaming","year":"2024","unstructured":"Vlaming M, Ausems MGEM, Schijven G et al (2024) Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.\u00a0Fam Cancer 23(2):165\u2013175","journal-title":"Familial cancer"},{"key":"27_CR74","doi-asserted-by":"crossref","unstructured":"Truong H, Breen K, Nandakumar S et al (2023) Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer. Eur Urol 83(1):29\u201338","DOI":"10.1016\/j.eururo.2022.08.028"},{"key":"27_CR75","doi-asserted-by":"crossref","unstructured":"Darst BF, Saunders E, Dadaev T et al (2023) Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer. JAMA Oncol 9(11):1514\u20131524","DOI":"10.1001\/jamaoncol.2023.3482"},{"key":"27_CR76","doi-asserted-by":"crossref","unstructured":"Stewart MD, Vega DM, Arend RC et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27(3):167\u2013174","DOI":"10.1093\/oncolo\/oyab053"},{"key":"27_CR77","doi-asserted-by":"crossref","unstructured":"Fan Y, Liu Z, Chen Y et al (2024) Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value. Adv Ther 41(6):2196\u20132216","DOI":"10.1007\/s12325-024-02844-7"},{"key":"27_CR78","doi-asserted-by":"crossref","unstructured":"Junejo NN, AlKhateeb SS (2020) BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. Saudi Med J 41(1):9\u201317","DOI":"10.15537\/smj.2020.1.24759"},{"key":"27_CR79","doi-asserted-by":"crossref","unstructured":"Bugoye FC, Torrorey-Sawe R, Biegon R et al (2023) Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. Front Genet 14:1231536","DOI":"10.3389\/fgene.2023.1231536"},{"key":"27_CR80","doi-asserted-by":"crossref","unstructured":"Hughley RW, Matejcic M, Song Z et al (2023) Polygenic risk score modifies prostate cancer risk of pathogenic variants in men of African ancestry. Cancer Res Commun 3(12):2544\u20132550","DOI":"10.1158\/2767-9764.CRC-23-0022"},{"key":"27_CR81","doi-asserted-by":"crossref","unstructured":"Stucci LS, Intern\u00f2 V, Tucci M et al (2021) The atm gene in breast cancer: Its relevance in clinical practice. Genes 12(5):727","DOI":"10.3390\/genes12050727"},{"key":"27_CR82","doi-asserted-by":"crossref","unstructured":"Grochot R, Carreira S, Miranda S et al (2023) Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. Eur Urol Open Sci 52:72\u201378","DOI":"10.1016\/j.euros.2023.04.003"},{"key":"27_CR83","doi-asserted-by":"crossref","unstructured":"Karlsson Q, Brook MN, Dadaev T et al (2021) Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL Consortium Study. Eur Urol Oncol 4(4):570\u2013579","DOI":"10.1016\/j.euo.2020.12.001"},{"key":"27_CR84","doi-asserted-by":"crossref","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38(5):395\u2013405","DOI":"10.1200\/JCO.19.01638"},{"key":"27_CR85","doi-asserted-by":"crossref","unstructured":"Woko\u0142orczyk D, Klu\u017aniak W, Stempa K et al (2021) PALB2 mutations and prostate cancer risk and survival. Br J Cancer 125(4):569\u2013575","DOI":"10.1038\/s41416-021-01410-0"},{"key":"27_CR86","doi-asserted-by":"crossref","unstructured":"Hanson H, Astiazaran-Symonds E, Amendola LM et al (2023) Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 25(10):100870","DOI":"10.1016\/j.gim.2023.100870"},{"key":"27_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","volume":"18","author":"GM Li","year":"2008","unstructured":"Li GM (2008) Mechanisms and functions of DNA mismatch repair.\u00a0Cell Res 18(1):85\u201398","journal-title":"Cell research"},{"key":"27_CR88","doi-asserted-by":"crossref","unstructured":"Rantapero T, Wahlfors T, K\u00e4hler A et al (2020) Inherited DNA repair gene mutations in men with lethal prostate cancer. Genes 11(3):314","DOI":"10.3390\/genes11030314"},{"key":"27_CR89","doi-asserted-by":"crossref","unstructured":"Pritchard CC, Morrissey C, Kumar A et al (2014) Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 5:4988","DOI":"10.1038\/ncomms5988"},{"key":"27_CR90","doi-asserted-by":"crossref","unstructured":"Sharma M, Yang Z, Miyamoto H (2020) Loss of DNA mismatch repair proteins in prostate cancer. Medicine 99(19):e20124","DOI":"10.1097\/MD.0000000000020124"},{"key":"27_CR91","doi-asserted-by":"crossref","unstructured":"Nourmohammadi Abadchi S, Sena LA, Antonarakis ES et al (2023) MLH1 Loss in Primary Prostate Cancer. JCO Precis Oncol 7:e2200611","DOI":"10.1200\/PO.22.00611"},{"key":"27_CR92","doi-asserted-by":"crossref","unstructured":"Bradford KC, Wilkins H, Hao P et al (2020) Dynamic human MutS\u03b1\u2013MutL\u03b1 complexes compact mismatched DNA. Proc. Natl Acad Sci USA 117(28):16302\u201316312","DOI":"10.1073\/pnas.1918519117"},{"key":"27_CR93","unstructured":"Bhattacharya P, Leslie SW, McHugh TW (2024) Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer). In StatPearls. StatPearls Publishing"},{"key":"27_CR94","doi-asserted-by":"crossref","unstructured":"Fukuhara S, Chang I, Mitsui Y et al (2015) Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Oncotarget 6(18):16341\u201316351","DOI":"10.18632\/oncotarget.3854"},{"key":"27_CR95","unstructured":"National Library of Medicine MSH2 gene. https:\/\/medlineplus.gov\/genetics\/gene\/msh2\/#:~:text=The%20MSH2%20protein%20joins%20with,been%20made%20during%20DNA%20replication"},{"key":"27_CR96","doi-asserted-by":"crossref","unstructured":"Guedes LB, Antonarakis ES, Schweizer MT et al (2017) MSH2 loss in primary prostate cancer. Clin Cancer Res : an official journal of the American Association for Cancer Research 23(22):6863\u20136874","DOI":"10.1158\/1078-0432.CCR-17-0955"},{"key":"27_CR97","doi-asserted-by":"crossref","unstructured":"McCoy P, Mangiola S, Macintyre G et al (2021) MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis 24(4):1167\u20131180","DOI":"10.1038\/s41391-021-00379-4"},{"key":"27_CR98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41391-022-00609-3","volume":"26","author":"F Marino","year":"2023","unstructured":"Marino F, Totaro A, Gandi C et al (2023) Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.\u00a0Prostate Cancer Prostatic Dis 26(4):655\u2013664","journal-title":"Prostate cancer and prostatic diseases"},{"key":"27_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14715\/cmb\/2023.69.2.1","volume":"69","author":"MA Ellatif","year":"2023","unstructured":"Ellatif MA, El-Gamal B, Musalam AO et al (2023) An update on genetic predisposition for prostate cancer: perspectives and prospects.\u00a0Cell Mol Biol 69(2):1\u20137","journal-title":"Cellular and molecular biology"},{"key":"27_CR100","doi-asserted-by":"crossref","unstructured":"Kadanga E, Zour\u00e9 AA, Zohoncon TM et al (2022) Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso. BMC Med Genom 15(1):123","DOI":"10.1186\/s12920-022-01279-9"},{"key":"27_CR101","doi-asserted-by":"crossref","unstructured":"Alvarez-Cubero MJ, Pascual-Geler M, Martinez-Gonzalez LJ et al (2016) Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk. Urol Oncol 34(10):431.e1\u2013431.e4318","DOI":"10.1016\/j.urolonc.2016.05.018"},{"key":"27_CR102","doi-asserted-by":"crossref","unstructured":"Dayal S, Zhou J, Manivannan P et al (2017) RNase l suppresses androgen receptor signaling, cell migration and matrix metalloproteinase activity in prostate cancer cells. Int J Mol Sci 18(3):529","DOI":"10.3390\/ijms18030529"},{"key":"27_CR103","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/s41416-023-02289-9","volume":"128","author":"W Lautert-Dutra","year":"2023","unstructured":"Lautert-Dutra W, Reis RB dos, Squire JA (2023) Precision medicine for prostate cancer\u2014improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier.\u00a0Br J Cancer 128(12):2163\u20132164","journal-title":"British journal of cancer"},{"key":"27_CR104","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00439-013-1331-2","volume":"132","author":"DN Cooper","year":"2013","unstructured":"Cooper DN, Krawczak M, Polychronakos C et al (2013) Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.\u00a0Hum Genet 132(10):1077\u20131130","journal-title":"Human genetics"},{"key":"27_CR105","doi-asserted-by":"crossref","unstructured":"Kote-Jarai Z, Leongamornlert D, Saunders E et al (2011) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105(8):1230\u20131234","DOI":"10.1038\/bjc.2011.383"},{"key":"27_CR106","doi-asserted-by":"crossref","unstructured":"Saunders EJ, Kote-jarai Z, Eeles RA (2021) Identification of germline genetic variants that increase prostate cancer risk and influence development of aggressive disease. Cancers 13(4):760","DOI":"10.3390\/cancers13040760"},{"key":"27_CR107","doi-asserted-by":"crossref","unstructured":"Tung N, Domchek SM, Stadler Z et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Clin Oncol 13(9):581\u2013588","DOI":"10.1038\/nrclinonc.2016.90"}],"container-title":["Methods in Molecular Biology","Circulating Tumor Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5050-9_27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:06:46Z","timestamp":1783634806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5050-9_27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650493","9781071650509"],"references-count":107,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5050-9_27","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"3 June 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}